Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Debt (2018 - 2019)

10x Genomics' Non-Current Debt history spans 2 years, with the latest figure at $19.8 million for Q4 2019.

  • For Q4 2019, Non-Current Debt fell 22.17% year-over-year to $19.8 million; the TTM value through Dec 2019 reached $19.8 million, down 22.17%, while the annual FY2019 figure was $19.8 million, 22.17% down from the prior year.
  • Non-Current Debt for Q4 2019 was $19.8 million at 10x Genomics, down from $22.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $25.5 million in Q4 2018 and bottomed at $19.8 million in Q4 2019.